SIA FUNDS, EL FONDO QUE CONFÍA EN GRÍFOLS SE POSICIONA EN CONTRA DE LA OPA .: Five-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma .